Shang Hai Zheng Quan Bao·2025-08-12 20:41Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of injection Nadir platinum by the National Medical Products Administration [2][4]. Drug Information and Research Status - The drug is a self-developed chemical product by the group, intended for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophageal cancer, bladder cancer, testicular cancer, ovarian cancer, and cervical cancer [3]. - As of July 2025, the cumulative R&D investment for this drug is approximately RMB 5.66 million (unaudited) [4]. - According to the latest IQVIA CHPA data, the projected sales for injection Nadir platinum in mainland China (excluding Hong Kong, Macau, and Taiwan) for 2024 is approximately RMB 353 million [4].